Altered expression and signalling of EP2 receptor in nasal polyps of AERD patients: role in inflammation and remodelling

Autor: César Picado, Laura Pujols, J. Roca-Ferrer, Maria Perez-Gonzalez, J Mullol, R Torres, L Machado-Carvalho, Isam Alobid
Rok vydání: 2017
Předmět:
Male
0301 basic medicine
medicine.medical_specialty
Prostaglandin E2 receptor
Respiratory Tract Diseases
Down-Regulation
Prostaglandin
Mucous membrane of nose
Inflammation
Stimulation
Dinoprostone
03 medical and health sciences
chemistry.chemical_compound
Nasal Polyps
0302 clinical medicine
Internal medicine
Cyclic AMP
Humans
Receptors
Prostaglandin E

Medicine
Nasal polyps
Alprostadil
Receptor
Cell Proliferation
Aspirin
business.industry
Anti-Inflammatory Agents
Non-Steroidal

Granulocyte-Macrophage Colony-Stimulating Factor
General Medicine
Fibroblasts
Middle Aged
medicine.disease
Nasal Mucosa
030104 developmental biology
Endocrinology
030228 respiratory system
Otorhinolaryngology
chemistry
Disease Progression
Female
lipids (amino acids
peptides
and proteins)

Signal transduction
medicine.symptom
business
Signal Transduction
Zdroj: Rhinology journal. 54:254-265
ISSN: 0300-0729
DOI: 10.4193/rhin15.207
Popis: Background: Down-regulation of the E-prostanoid (EP)2 receptor has been reported in aspirin exacerbated respiratory disease (AERD). We aimed to evaluate the expression and activation of EP receptors in AERD and their role in prostaglandin (PG) E2 signalling. Methods: Samples were obtained from nasal mucosa of control subjects (NM-C, n=7) and from nasal polyps of AERD patients (NP-AERD, n=7). Expression of EP1-4 was assessed at baseline. Fibroblasts were stimulated with receptor agonists to measure cAMP levels, cell proliferation and granulocyte-macrophage colony-stimulating factor (GM-CSF) release. Results: NM-C and NP-AERD samples and fibroblasts expressed EP2, EP3 and EP4 at baseline. Lower expression of EP2 and higher expression of EP4 was observed in NP-AERD compared with NM-C. Stimulation with PGE2 and butaprost caused a higher increase in cAMP in NM-C than in NP-AERD. On the contrary, CAY10598 produced a higher production of cAMP in NP-AERD compared with NM-C. The anti-proliferative effect of PGE2 and butaprost was lower in NP-AERD than in NM-C fibroblasts. Similarly, the capacity of PGE2 and butaprost to inhibit GM-CSF release was lower in NP-AERD than in NM-C. Conclusions: The altered expression of EP2 in AERD may contribute to reduce the capacity of PGE2 to mediate anti-proliferative and anti-inflammatory effects.
Databáze: OpenAIRE